VYNE Therapeutics's total assets for Q1 2025 were $56.42M, a decrease of -15.67% from the previous quarter. VYNE total liabilities were $12.29M for the fiscal quarter, a -17.06% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.